NGM Biopharmaceuticals Future Growth
Future criteria checks 2/6
NGM Biopharmaceuticals is forecast to grow earnings and revenue by 14.7% and 57.6% per annum respectively. EPS is expected to grow by 20.3% per annum. Return on equity is forecast to be -230.7% in 3 years.
Key information
14.7%
Earnings growth rate
20.3%
EPS growth rate
| Pharmaceuticals earnings growth | 23.8% |
| Revenue growth rate | 57.6% |
| Future return on equity | -230.7% |
| Analyst coverage | Low |
| Last updated | 12 Mar 2024 |
Recent future growth updates
Recent updates
What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You
Dec 19
We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate
Oct 05Some Analysts Just Cut Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Estimates
Aug 09Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky
Jun 27NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Business Is Trailing The Industry But Its Shares Aren't
Apr 17We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully
Dec 20NGM Biopharma sinks ~72% after phase 2 trial of its eye degeneration treatment fails
Oct 17NGM Biopharmaceuticals appoints CFO Siobhan Nolan Mangini to the additional role of President
Jun 30NGM Biopharmaceuticals: Eye Disorder Data Due Second Half Of 2022
Jun 21Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth
Jun 15Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week
May 09NGM Biopharmaceuticals: How They Changed A Dead End To A Crossroad
Apr 26Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth
Feb 21We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely
Nov 08Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth
Jul 09NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Mar 06Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 9 | -90 | -88 | -46 | 4 |
| 12/31/2025 | 0 | -94 | -89 | -78 | 5 |
| 12/31/2024 | 0 | -98 | -77 | -69 | 3 |
| 12/31/2023 | 4 | -142 | -133 | -132 | N/A |
| 9/30/2023 | 22 | -151 | -141 | -140 | N/A |
| 6/30/2023 | 30 | -170 | -142 | -141 | N/A |
| 3/31/2023 | 37 | -178 | -153 | -151 | N/A |
| 12/31/2022 | 55 | -163 | -146 | -144 | N/A |
| 9/30/2022 | 58 | -153 | -134 | -132 | N/A |
| 6/30/2022 | 69 | -135 | -115 | -114 | N/A |
| 3/31/2022 | 77 | -125 | -89 | -87 | N/A |
| 12/31/2021 | 78 | -120 | -75 | -73 | N/A |
| 9/30/2021 | 77 | -121 | -77 | -75 | N/A |
| 6/30/2021 | 82 | -122 | -93 | -91 | N/A |
| 3/31/2021 | 85 | -111 | -88 | -87 | N/A |
| 12/31/2020 | 87 | -102 | -85 | -83 | N/A |
| 9/30/2020 | 99 | -90 | -81 | -78 | N/A |
| 6/30/2020 | 97 | -72 | -62 | -60 | N/A |
| 3/31/2020 | 102 | -54 | -50 | -48 | N/A |
| 12/31/2019 | 104 | -43 | -45 | -41 | N/A |
| 9/30/2019 | 120 | -13 | -22 | -20 | N/A |
| 6/30/2019 | 119 | -9 | -22 | -19 | N/A |
| 3/31/2019 | 116 | -5 | -22 | -15 | N/A |
| 12/31/2018 | 109 | 0 | -13 | -8 | N/A |
| 9/30/2018 | 81 | -17 | -24 | -18 | N/A |
| 6/30/2018 | 80 | -12 | -22 | -15 | N/A |
| 3/31/2018 | 77 | -13 | -21 | -16 | N/A |
| 12/31/2017 | 77 | -14 | -24 | -17 | N/A |
| 12/31/2016 | 86 | -7 | N/A | 1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NGM is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NGM is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NGM is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NGM's revenue (57.6% per year) is forecast to grow faster than the US market (8.1% per year).
High Growth Revenue: NGM's revenue (57.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NGM is forecast to be unprofitable in 3 years.